MEKINIST (trametinib) Patient Assistance Program
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey.
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Mekinist (trametinib) is FDA-approved (in combination with Tafinlar/dabrafenib) for BRAF V600-mutated unresectable or metastatic melanoma, BRAF V600E-mutated metastatic NSCLC, BRAF V600E-mutated anaplastic thyroid cancer, BRAF V600E-mutated solid tumors (tumor-agnostic), and pediatric BRAF V600E glioma. As monotherapy it is approved for BRAF V600E or V600K melanoma in patients with no prior BRAF inhibitor therapy.
- Without assistance, Mekinist costs commonly run approximately $12,000–$14,500 per 30-day supply.
- Through AffordMyPrescriptions, qualifying patients can access Mekinist for a flat $69.95 per month — our advocacy team manages the entire enrollment, refills, and renewal process.
- There is no generic Mekinist in the U.S. as of 2026. Other MEK inhibitors include binimetinib (Mektovi, paired with encorafenib/Braftovi), cobimetinib (Cotellic, paired with vemurafenib/Zelboraf), and selumetinib (Koselugo, for plexiform neurofibromas in NF1).
What Is Mekinist Prescription Assistance Program?
The Mekinist Prescription Assistance Program is a manufacturer-sponsored initiative that provides Mekinist at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for BRAF-mutated cancer patients who are uninsured or underinsured, as well as Medicare Part D beneficiaries.
Navigating the program on your own means dealing with eligibility verification, oncology coordination, BRAF mutation testing documentation, prior-authorization documentation, specialty pharmacy logistics, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing refill coordination and re-certification.
Pharmacy Price Comparison
- Without assistance, Mekinist costs roughly $12,000–$14,500/month. A Patient Assistance Program is the meaningful path forward — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$14,000 | Save ~$13,930/mo |
| CVS Pharmacy | ~$14,500 | Save ~$14,430/mo |
| Walmart | ~$12,500 | Save ~$12,430/mo |
| Costco | ~$12,200 | Save ~$12,130/mo |
Specialty Pharmacy | ~$13,000 | Save ~$12,930/mo |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Mekinist Prescription Program?
The Patient Assistance Program is free to apply for and provides Mekinist at no medication cost if approved. Our $69.95/month service covers full advocacy.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Mekinist:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
Still $12,000–$14,500 per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
- We manage all paperwork, refills, and annual renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Mekinist assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Mekinist Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Understanding Mekinist:
Mekinist (trametinib) is a once-daily oral selective inhibitor of MEK1/MEK2 kinases used to treat cancers driven by activating BRAF V600 mutations. It is typically used in combination with the BRAF inhibitor dabrafenib (Tafinlar) for synergistic activity and delay of resistance.
How Mekinist Works:
BRAF V600-mutated cancers rely on an overactive MAPK signaling pathway—running from RAF to MEK to ERK—to drive continuous cell growth and survival. Trametinib works by selectively inhibiting MEK1 and MEK2, the specific kinases located immediately downstream of RAF, effectively shutting down ERK activation. While cancers often develop resistance to standalone BRAF inhibitors by reactivating downstream pathways, blocking MEK directly bypasses this workaround. Combining a BRAF inhibitor with a MEK inhibitor successfully delays drug resistance, increases patient survival rates, and minimizes certain monotherapy side effects like paradoxical skin cancers.
Form and use:
Mekinist is an oral medication with a standard recommended dosage of 2 mg taken once daily. To ensure proper absorption, it must always be taken on an empty stomach, meaning at least 1 hour before or 2 hours after a meal. This medication is typically prescribed in combination with Tafinlar (dabrafenib) at a dose of 150 mg taken twice daily. Patients generally continue this combination regimen until their disease progresses or they experience unacceptable toxicity.
Generic availability:
As of 2026, there is no generic version of Mekinist available for patients in the United States. Healthcare providers can choose from other approved MEK inhibitors on the market, such as binimetinib, cobimetinib, or selumetinib, the latter of which is used for plexiform neurofibromas. For treating BRAF V600-mutated melanoma, there are three primary approved BRAF and MEK inhibitor combinations. These options include Tafinlar paired with Mekinist, Braftovi paired with Mektovi, and Zelboraf paired with Cotellic.
Warnings:
Mekinist carries serious warnings for developing new primary cancers, severe bleeding, high blood pressure, and lung inflammation. It can cause heart issues like cardiomyopathy with decreased LVEF, requiring regular echocardiograms, as well as blood clots and severe skin or febrile reactions. Vision-threatening ocular toxicities like retinal detachment or vein occlusion necessitate baseline eye exams and immediate evaluation for any vision changes. Additionally, it presents risks for gastrointestinal perforation or colitis, and because it causes embryo-fetal toxicity, it must never be used in tumors without the BRAF mutation.
FAQ (Frequently Asked Questions)
How Much Does Mekinist Cost Without Insurance?
Mekinist costs approximately $12,000–$14,500 per 30-day supply. When combined with Tafinlar (dabrafenib), monthly costs commonly exceed $25,000–$30,000+. Through AffordMyPrescriptions, qualifying patients receive Mekinist at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
Why Take Mekinist And Tafinlar Together?
BRAF monotherapy (dabrafenib alone) initially produces strong responses, but resistance develops within months because cancer cells reactivate the MAPK pathway downstream of BRAF. Adding the MEK inhibitor trametinib (Mekinist) — which blocks the next kinase in the pathway — delays resistance, improves response rates and progression-free survival, and reduces certain BRAF-monotherapy side effects (paradoxical skin cancers). The combination is now standard for BRAF V600-mutated cancers.
Why Do I Need Echocardiograms On Mekinist?
MEK inhibitors can cause cardiomyopathy with decreased left ventricular ejection fraction (LVEF). LVEF should be assessed at baseline, after 1 month, and every 2–3 months during therapy. If LVEF drops significantly below baseline, Mekinist may need to be held or stopped. Tell your oncologist about new shortness of breath, leg swelling, palpitations, or chest pain.
Why Do I Need Eye Exams On Mekinist?
MEK inhibitors can cause serious ocular toxicities including retinal detachment, retinal vein occlusion, and uveitis. Baseline ophthalmologic exam is recommended, and any new vision changes (blurring, floaters, flashes, dark spots, pain, redness) require prompt evaluation. Mekinist should be held or stopped for significant ocular toxicity.
How Will My Doctor Monitor For Side Effects?
LVEF (echo or MUGA), LFTs, CBC, comprehensive metabolic panel, blood pressure, skin checks, and ophthalmologic evaluation are all done at baseline and periodically. Fevers, GI symptoms, and rash should be reported promptly. The combination of Tafinlar + Mekinist has more side effects than either alone but better cancer outcomes.
Can I Get Mekinist Through The PAP If I Have Medicare?
Yes. Medicare Part D beneficiaries can typically qualify, especially if you face specialty-tier copays. The manufacturer’s commercial copay savings program is reserved for commercially insured patients only — but the underlying PAP supports Medicare patients who meet income criteria.Yes. Medicare Part D beneficiaries can typically qualify, especially if you face specialty-tier copays. The manufacturer’s commercial copay savings program is reserved for commercially insured patients only — but the underlying PAP supports Medicare patients who meet income criteria.
What If My Application Is Denied?
If you are struggling with the high cost of Mekinist, our team may be able to help you access assistance programs designed to make brand specialty MEK-targeted oncology therapy affordable. Check your eligibility today.
Take Control of Your Medication Costs
If you are struggling with the high cost of Keytruda, our team may be able to help you access assistance programs designed to make brand specialty checkpoint inhibitor immunotherapy affordable. Check your eligibility today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.